Literature DB >> 19135042

Cholesterol efflux from J774 macrophages and Fu5AH hepatoma cells to serum is preserved in CETP-deficient patients.

Kenji Miwa1, Akihiro Inazu, Masaaki Kawashiri, Atsushi Nohara, Toshinori Higashikata, Junji Kobayashi, Junji Koizumi, Katsuyuki Nakajima, Takamitsu Nakano, Manabu Niimi, Hiroshi Mabuchi, Masakazu Yamagishi.   

Abstract

BACKGROUND: The role of CETP in the development of atherosclerosis is debatable, and few data exist regarding the total impact of CETP inhibition on cholesterol efflux.
METHODS: Acceptor capacities of whole serum and HDL subfractions separated by HPLC were compared using 2 different cell systems. Subjects with CETP deficiency (2 homozygous, 1 compound heterozygous, and 5 heterozygous) were analyzed along with 10 normolipidemic controls. The fractional efflux from cholesterol-labeled Fu5AH hepatoma cells was determined to be SR-BI mediated. The efflux difference between control and liver X receptor (LXR) agonist-induced ABCA1-upregulated J774 macrophages was considered as a measure of ABCA1-mediated efflux.
RESULTS: For the Fu5AH cell system, the total acceptor capacities of whole serum and HPLC-separated HDL fraction 2 obtained from the homozygous subjects were 38% and 116% higher than the corresponding values for the controls, respectively (p<0.05). For the J774 cell system, the total acceptor capacities of whole serum and HPLC-separated HDL fractions were similar among the CETP-deficient subjects and controls.
CONCLUSIONS: Serum from homozygous subjects with CETP-null defects exhibited enhanced acceptor capacity via an SR-BI dependent pathway, which is regulated by the middle HPLC-separated HDL fraction. Further, the cholesterol acceptor capacity of serum obtained from patients having complete and partial CETP deficiency was preserved via an ABCA1-dependent pathway.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 19135042     DOI: 10.1016/j.cca.2008.12.012

Source DB:  PubMed          Journal:  Clin Chim Acta        ISSN: 0009-8981            Impact factor:   3.786


  5 in total

Review 1.  Current perspectives in genetic cardiovascular disorders: from basic to clinical aspects.

Authors:  Masa-aki Kawashiri; Kenshi Hayashi; Tetsuo Konno; Noboru Fujino; Hidekazu Ino; Masakazu Yamagishi
Journal:  Heart Vessels       Date:  2013-08-02       Impact factor: 2.037

2.  Anacetrapib promotes reverse cholesterol transport and bulk cholesterol excretion in Syrian golden hamsters.

Authors:  Jose Castro-Perez; François Briand; Karen Gagen; Sheng-Ping Wang; Ying Chen; David G McLaren; Vinit Shah; Rob J Vreeken; Thomas Hankemeier; Thierry Sulpice; Thomas P Roddy; Brian K Hubbard; Douglas G Johns
Journal:  J Lipid Res       Date:  2011-08-14       Impact factor: 5.922

Review 3.  Cholesteryl ester transfer protein (CETP) deficiency and CETP inhibitors.

Authors:  Hiroshi Mabuchi; Atsushi Nohara; Akihiro Inazu
Journal:  Mol Cells       Date:  2014-11-06       Impact factor: 5.034

4.  High-density lipoprotein (HDL) particle subpopulations in heterozygous cholesteryl ester transfer protein (CETP) deficiency: maintenance of antioxidative activity.

Authors:  Sandrine Chantepie; Andrea E Bochem; M John Chapman; G Kees Hovingh; Anatol Kontush
Journal:  PLoS One       Date:  2012-11-26       Impact factor: 3.240

Review 5.  High Density Lipoprotein Cholesterol Efflux Capacity and Atherosclerosis in Cardiovascular Disease: Pathophysiological Aspects and Pharmacological Perspectives.

Authors:  Maria Pia Adorni; Nicoletta Ronda; Franco Bernini; Francesca Zimetti
Journal:  Cells       Date:  2021-03-05       Impact factor: 7.666

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.